公开(公告)号：US20240079111A1

公开(公告)日：2024-03-07

申请号：US18454323

申请日：2023-08-23

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D’ARCO ,  Jason O'CONNOR

IPC: G16H20/17 ,  A61M5/142

CPC classification number: G16H20/17 ,  A61M5/142 ,  A61M2005/14208

Abstract: Disclosed herein is a method, implemented in an automatic drug delivery system, for determining insulin resistance of a user and adjusting parameters of the medication delivery algorithm of the automatic drug delivery system based on the determined insulin resistance. A self-guided test is administered similar to the Kraft test which determines if the quantity of insulin delivered during a post-prandial period after ingestion of a quantity of fast-acting carbohydrates is sufficient to lower the user's blood glucose level to a baseline level.

公开(公告)号：US20240058534A1

公开(公告)日：2024-02-22

申请号：US18499515

申请日：2023-11-01

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2005/14208 ,  A61M2205/3303 ,  A61M2205/3569 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide techniques to implement functionality to receive blood glucose measurements over a period of time. An average of missing blood glucose measurement values may be maintained over a predetermined time period. A count of a number of missing blood glucose measurement values over a period of time may be established. A controller may calculate a divergence of the number of missing blood glucose measurement values over the period of time from the average of missing blood glucose measurements over the predetermined time period. Based on a value of the divergence, a determination that a safety constraint for delivery of insulin is to be reduced. The safety constraint may be reduced by a predetermined percentage. An instruction to deliver an insulin dosage may be generated according to the reduced safety constraint may be forwarded to a wearable drug delivery device.

公开(公告)号：US20230285670A1

公开(公告)日：2023-09-14

申请号：US18119059

申请日：2023-03-08

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Mengdi LI

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2202/0486 ,  A61M2205/50 ,  A61M2205/52

Abstract: The exemplary embodiments may provide adaptivity in the basal portion value. The exemplary embodiments may also provide adaptivity of the total daily medicament (TDM) delivery amount. The adaptivity provided by the exemplary embodiments helps to customize medicament delivery to the needs of the user of a medicament delivery device. The exemplary embodiments may adapt the basal ratio for the user based on historical medicament delivery data for the user. In addition, the exemplary embodiments may update the basal ratio based upon more recent trends that diverge from the historical medicament delivery data. The degree of adaptivity provided by the exemplary embodiments may be bound to not exceed an upper threshold and/or a lower threshold. The degree of adaptivity may be modulated by controlling the rate of adaptivity too small increments each time the basal ratio is updated.

公开(公告)号：US20230277766A1

公开(公告)日：2023-09-07

申请号：US18316703

申请日：2023-05-12

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142 ,  A61K38/28 ,  G16H20/17 ,  G16H40/67 ,  G05D7/06 ,  G05B15/02

CPC classification number: A61M5/172 ,  A61M5/14248 ,  A61K38/28 ,  G16H20/17 ,  G16H40/67 ,  G05D7/0623 ,  G05D7/0676 ,  G05B15/02 ,  A61M2205/18 ,  A61M2205/52 ,  A61M2205/3331 ,  A61M2205/3584

Abstract: Disclosed are techniques to establish a modified pump rate that mitigates the effects of a pump occlusion and enables a recommended dosage of insulin to be output by a pump mechanism over the course of a control cycle. In an example, the pump rate may be reduced by adding a calculated time interval between application of actuation commands to extend the amount of time over which insulin may be output by the pump mechanism.

公开(公告)号：US20230233764A1

公开(公告)日：2023-07-27

申请号：US18157400

申请日：2023-01-20

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Graeme NELSON

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2205/52 ,  A61M2205/502 ,  A61M2230/201

Abstract: Disclosed are a computing apparatus, a computer-readable medium and a method that enable a user to use subjective inputs to alter settings of a wearable automatic drug delivery system. A user input device is presented on a graphical user interface that enables input of a subjective insulin need parameter. In response to receiving the input, the processor may modify a subjective coefficient value. A specific factor useable by an automatic insulin delivery algorithm is set based on the subjective coefficient value. Physiological condition data related to the user and the set specific factor may be used to determine a dosage of insulin to be delivered to the user based on the collected physiological condition data of the user. The processor may cause the determined dosage of insulin to be delivered to the user based on an output of the automatic insulin delivery algorithm.

公开(公告)号：US20230230668A1

公开(公告)日：2023-07-20

申请号：US18155215

申请日：2023-01-17

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Rangarajan NARAYANASWAMI ,  Yibin ZHENG ,  Ashutosh ZADE ,  Jason O'CONNOR

IPC: G16H20/17 ,  A61M5/172 ,  A61M5/142

CPC classification number: G16H20/17 ,  A61M5/1723 ,  A61M5/142 ,  A61M2205/52 ,  A61M2005/14208 ,  A61M2230/201

Abstract: Disclosed herein are systems and methods for providing safeguards, in an automatic drug delivery system, to prevent or compensate for insufficient delivery of bolus doses of a liquid drug. The safeguards include, for example, features built into the medication delivery algorithm to allow the medication delivery algorithm to ensure that proper bolus doses are delivered, either manually by the user or automatically by the drug delivery system. In addition, various methods are described for providing the medication delivery algorithm with a means for determining when a meal has been ingested and, in some embodiments, for providing an automatic bolus dose of the liquid drug in response to the determination.

公开(公告)号：US20230095302A1

公开(公告)日：2023-03-30

申请号：US17935483

申请日：2022-09-26

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Bonnie DUMAIS ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  A61M5/142

Abstract: Disclosed are techniques and devices that are operable to receive one or a number of generalized parameters of an automated insulin delivery algorithm. An input of at least one generalized parameter corresponding to a user may be used to set one or more of the number of specific parameters of the automated insulin delivery algorithm based on the inputted at least one generalized parameter. Physiological condition data related to the user may be collected. The automated insulin delivery algorithm may determine a dosage of insulin to be delivered based on the collected physiological condition. Signals may be output to cause a liquid drug to be delivered to the user based on an output of the automated insulin delivery algorithm related to the determined dosage of insulin.

公开(公告)号：US20230067014A1

公开(公告)日：2023-03-02

申请号：US17821989

申请日：2022-08-24

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D'ARCO ,  David NAZZARO ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/315 ,  A61M5/20

Abstract: The exemplary embodiments may account for a change in potency of a medicament and adjust the dosage of medicament delivered to a user via a medicament delivery device to compensate for the change in potency. The medicament delivery device may determine the amount of change in the potency in the medicament and may make the adjustment in dosage of the medicament delivered to the user automatically without user input. The net result in that the dosage of medicament delivered to the user is better matched to the user's true need for the medicament.

公开(公告)号：US20230062884A1

公开(公告)日：2023-03-02

申请号：US17821994

申请日：2022-08-24

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  M. Thomas ANDERSEN

IPC: A61M5/315 ,  A61M5/20

Abstract: Disclosed are processes and techniques for a drug delivery system to maintain optimal drug delivery for a patient according to a treatment plan. The disclosed techniques enable a drug delivery system to delivery adjusted drug dosages and/or drug delivery cost function aggressiveness factors modified based on clusters or patterns of patient drug dosages and/or response event probabilities. For example, a controller for operating a drug delivery device may operate to determine a plurality of dosage clusters for a patient based on drug dosage patient information, determine an adjustment profile for each of the dosage clusters, determine a current cluster for a dosage cycle, determine an adjusted dosage for the dosage cycle by applying the adjustment profile to a default dosage, and provide a signal to the drug delivery device to deliver the adjusted dosage to the patient for the dosage cycle. Other embodiments are described.

公开(公告)号：US20230001088A1

公开(公告)日：2023-01-05

申请号：US17848673

申请日：2022-06-24

Applicant: INSULET CORPORATION

Inventor： Ashutosh ZADE ,  Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

Abstract: The switchover between an expiring on-body medicament delivery device and a replacement on-body medicament is made to eliminate or significantly decrease the time where an on-body medicament delivery device is operational to deliver medicament to a user. The replacement on-body medicament device is attached to the user and prepped for operation while the expiring on-body medicament delivery device is still operational. The switchover between on-body sensors also may be improved. Methods for calibrating a replacement on-body sensor while the expiring on-body sensor is still operative are provided. The calibrating may be performed quickly so that there is no gap in operation between expiration of the expiring on-body sensor and full operation of the replacement on-body sensor.